Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
pixel
George B. Abercrombie, insider at BioCryst Pharmaceuticals

George B. Abercrombie Insider Information

George B. Abercrombie serves as Independent Director of the Company. Mr. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. Mr. Abercrombie held the position of Senior Vice President and Chief Commercial Officer at Innoviva, Inc., a publicly traded bio-pharmaceutical asset management company, from 2014 to 2018. He served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible leading operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie also serves on the Board of Brickell Biotech, a private pharmaceutical company. He formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc., Ziopharm Oncology, Inc, Tranzyme Pharma, Aptus Health, Inc. and DemeRX. Additionally, he is an Adjunct Professor at Duke University’s Fuqua School of Business and a board member of the North Carolina GlaxoSmithKline Foundation. He previously served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Pub.

What is George B. Abercrombie's net worth?

The estimated net worth of George B. Abercrombie is at least $144,231.64 as of May 24th, 2021. Mr. Abercrombie owns 9,667 shares of BioCryst Pharmaceuticals stock worth more than $144,232 as of September 26th. This net worth approximation does not reflect any other investments that Mr. Abercrombie may own. Learn More.

How do I contact George B. Abercrombie?

The corporate mailing address for Mr. Abercrombie and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]

Has George B. Abercrombie been buying or selling shares of BioCryst Pharmaceuticals?

In the last ninety days, George B. Abercrombie has sold $1,116,660.00 in BioCryst Pharmaceuticals stock. Most recently, George B. Abercrombie sold 74,000 shares of the business's stock in a transaction on Friday, September 10th. The shares were sold at an average price of $15.09, for a transaction totalling $1,116,660.00.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Alane Barnes (Insider), Nancy Hutson (Director), and William Sheridan (Insider).

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 318,021 shares worth mmore than $4,278,916.67. The most recent insider tranaction occured on September, 10th when George B Abercrombie Director bought 74,000 shares worth more than $1,116,660.00. Insiders at BioCryst Pharmaceuticals own 4.8 % of the company.

Information on this page was last updated on 9/10/2021.

George B. Abercrombie Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2021Sell74,000$15.09$1,116,660.00View SEC Filing Icon  
5/24/2021Sell6,667$13.90$92,671.309,667View SEC Filing Icon  
5/10/2021Sell7,000$12.70$88,900.003,000View SEC Filing Icon  
3/5/2013Buy3,000$1.23$3,690.00View SEC Filing Icon  
See Full Table

George B. Abercrombie Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows George B Abercrombie's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. It focuses on the oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The company was founded in 1986 and is headquartered in Durham, NC.
Read More

Today's Range

Now: $14.92
Low: $14.91
High: $15.30

50 Day Range

MA: $15.80
Low: $14.21
High: $17.65

2 Week Range

Now: $14.92
Low: $3.36
High: $18.48

Volume

2,112,855 shs

Average Volume

4,584,605 shs

Market Capitalization

$2.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.59
The $7 Secret to $1,000 in Upfront Payouts
Extract $500... $1,000... even $1,500 in upfront payments from some of the market's hottest blue chip companies... without buying a single option.

It's unlike anything you've seen before, and it's never been more affordable to get started.
Click here for details.
pixel